Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2474 • 2013 ACR/ARHP Annual Meeting
Fat Mass and Resistin: Predictive Factors For Anti-TNF Therapy Response In Ankylosing Spondylitis Patients
Carla G.S. Saad¹, Andressa Silva Abreu¹, Ana Cristina Medeiros Ribeiro¹, Julio C. B. Moraes², Luiz A. Perandini¹, Thalita Dassouki³, Rosa M. R. Pereira⁴, Eloisa Bonfa⁵ and Ana Lucia S. Pinto¹, ¹Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Reumatologia, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, ⁵Rheumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: The adipose tissue immune properties and pharmacokinetic consequences can contribute to the pathogenesis of inflammatory conditions. The hole of fat tissue in active Ankylosing…
Abstract Number: 2449 • 2013 ACR/ARHP Annual Meeting
Patient-Reported Disease Activity and Outcome In Male Versus Female Patients Of The Groningen Leeuwarden Axial Spondyloarthritis (GLAS) Cohort
Suzanne Arends^1,2, Fiona Maas¹, Eveline van der Veer³, Reinhard Bos², Monique Efde², Martha K. Leijsma¹, Hendrika Bootsma¹, Elisabeth Brouwer¹ and Anneke Spoorenberg¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Ankylosing Spondylitis (AS) occurs more often in males than in females. Most women tend to have milder disease and may therefore be underdiagnosed. Male…
Abstract Number: 1543 • 2013 ACR/ARHP Annual Meeting
Patients With Ankylosing Spondylitis Are Substantially Undertreated For Hypertension and Hypercholesterolemia
Sjoerd C. Heslinga^1,2,3, Inge A.M. van den Oever¹, Alper M. van Sijl^2,4, Irene E. Van der Horst-Bruinsma^4,5 and Michael. T. Nurmohamed^2,4, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Internal Medicine, VU University Medical Center, Amsterdam, Netherlands, ⁴Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁵Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients with ankylosing spondylitis (AS) have a decreased life expectancy due to an increased cardiovascular (CV) risk. The general inflammatory process is held responsible…
Abstract Number: 1514 • 2013 ACR/ARHP Annual Meeting
Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register
Saedis Saevarsdottir¹, Michele Santacatterina², Leszek Stawiarz³, Carl Turesson⁴, Helena Forsblad⁵, Lennart T.H. Jacobsson⁶ and Staffan Lindblad⁷, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ⁴Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ⁵Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁷Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)…
Abstract Number: 401 • 2013 ACR/ARHP Annual Meeting
Chest Pain Is Not Associated With Coronary Atherosclerosis In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Silvia Rollefstad¹, Eirik Ikdahl², Inge C. Olsen³, Jonny Hisdal⁴, Tore K. Kvien^5,6, Anne S. Eirheim², Terje R. Pedersen⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Section of Vascular Investigations, Uslo University Hospital-Aker, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose: During cardiovascular (CV) risk stratification in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS), it can be difficult to distinguish between chest pain…
Abstract Number: 2479 • 2013 ACR/ARHP Annual Meeting
Adalimumab Significantly Reduces Inflammation In Active Ankylosing Spondylitis: An Ultrasound Study
Zaiying Hu¹, Manlong Xu², Zetao Liao³, Zhiming Lin⁴ and Jieruo Gu⁵, ¹Rheumatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²THIRD AFFILIATED HOSPITAL OF SUN YAT-SEN UNIVERSIT, Guangzho, China, ³Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ⁴Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ⁵Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: To evaluate the feasibility of using power Doppler ultrasound (PDUS) to detect inflammation in sacroiliac joints and entheses after adalimumab (a TNF-alpha antagonist) treatment…
Abstract Number: 2354 • 2013 ACR/ARHP Annual Meeting
Drug Survival Rates Of Anti-Tumor Necrosis Factor Therapies In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Dong-Jin Park¹, Kyung-Eun Lee¹, Ji-Hyoun Kang², Jeong-Won Lee², Tae-Jong Kim³, Yong-Wook Park¹ and Shin-Seok Lee⁴, ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Chonnam National University Medical School, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ⁴Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: We investigated the compliance of Korean patients using anti-tumor necrosis factor (TNF) agents to treat rheumatoid arthritis (RA) and anklyosing spondylitis (AS), and identified…
Abstract Number: 1547 • 2013 ACR/ARHP Annual Meeting
How The Delay In Diagnosis Impacts On The Clinical, Functional and Radiographic Status Of Patients With Ankylosing Spondylitis. Is There a Window Of Opportunity?
luis Alejandro Cayetti¹, Emilce Schneeberger¹, Natalia Zamora², Fernando Sommerfleck² and Gustavo Citera², ¹Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: The delay in diagnosis has deleterious effects in patients with Rheumatoid Arthritis. This fact has not been fully investigated in patients with Ankylosing Spondylitis…
Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Gabriela Ávila¹, Sara Marsal¹, Arnald Alonso¹, Carolina Diaz², Estefanía Quesada-Masachs², María López-Lasanta¹ and Isabel Acosta³, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Rheumatology, University Hospital Vall d'Hebron, Barcelona, Spain, ³Vall d'Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
Abstract Number: 384 • 2013 ACR/ARHP Annual Meeting
Carotid Artery Plaques Are Associated With Coronary Atherosclerosis In Patients With Inflammatory Joint Diseases Independent Of Several Cardiovascular Risk Calculators
Silvia Rollefstad¹, Eirik Ikdahl², Inge C. Olsen³, Tore K. Kvien^4,5, Anne S. Eirheim², Terje R. Pedersen^4,6 and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway
Background/Purpose: Patients with rheumatoid arthritis (RA) and carotid plaque (CP) have been shown to have increased risk of future acute coronary syndrome. We have established…
Abstract Number: 2489 • 2013 ACR/ARHP Annual Meeting
Spondyloarthritis-Associated Polymorphisms Of ERAP1 Are Correlated With Gene Expression, Protein Level and Enzymatic Activity Of The Amino-Peptidase
Félicie Costantino¹, Alice Talpin², Irini Evnouchidou³, Amir Kadi², Roula Said-Nahal⁴, Ariane Leboime⁵, Nelly Bonilla⁶, Franck Letourneur⁶, Tifenn Leturcq², Zeyna Ka², Peter van Endert³, Henri-Jean Garchon^2,7, Gilles Chiocchia^8,9 and Maxime A. Breban^2,7, ¹INSERM U987, Faculté des Sciences de la Santé Simone Veil, Montigny-le-Bretonneux, France, ²Institut Cochin - Université Paris Descartes - INSERM U1016 - CNRS (UMR 8104), Paris, France, ³INSERM U1013 - Université Paris Descartes - Sorbonne Paris Cité, Paris, France, ⁴Rheumatology Division, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁵Rheumatology Division, Ambroise-Paré Hospital AP-HP, Boulogne-Billancourt, France, ⁶INSERM U1016, Cochin Institute, Paris, France, ⁷Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, ⁸Versailles Saint Quentin en Yvelines University, INSERM U987, UFR des Sciences de la Santé, Montigny-le-Bretonneux, France, ⁹Université Versailles-Saint Quentin, Montigny le Bretonneux, France
Background/Purpose: Endoplasmic reticulum aminopeptidase 1 (ERAP1) exerts a central role in antigen presentation making it an attractive candidate gene for inflammatory diseases. Several polymorphisms in…
Abstract Number: 2348 • 2013 ACR/ARHP Annual Meeting
Long Term Safety Of Intravenous Golimumab and Comparisons With Subcutaneous Golimumab In Rheumatologic Conditions: Results From The 120-Day Safety Report Of a Phase 3 Trial Of Intravenous Golimumab
Rene Westhovens¹, Clifton O. Bingham III², Michael E. Weinblatt³, Roy Fleischmann⁴, Edward C. Keystone⁵, Elizabeth C. Hsia⁶, Benjamin Hsu⁶, Lilianne Kim⁶, Surekha Mudivarthy⁶, Michael Mack⁷, Neil Goldstein⁶, Jürgen Braun⁸, Arthur Kavanaugh⁹, Alan M. Mendelsohn¹⁰ and Jonathan Kay¹¹, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁸PsAID taskforce, EULAR, Zurich, Switzerland, ⁹University of California San Diego, San Diego, CA, ¹⁰Immunology, Janssen Research & Development, LLC., Spring House, PA, ¹¹UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: To describe safety profile of IV GLM in RA from the Ph3 GLM IV program. AE rates of interest are indirectly compared to…
Abstract Number: 1548 • 2013 ACR/ARHP Annual Meeting
Effect Of TNF Inhibitors On Bone Mineral Density In Patients With Ankylosing Spondylitis- a Systematic Review and Meta-Analysis
Nisha Nigil Haroon¹, Jeevitha Srighanthan², Nayef AL Ghanim³, Robert D. Inman^4,5,6,7,8,9 and Angela Cheung¹⁰, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Osteoporosis Program, University of Toronto, Ontario, ON, Canada, ³Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Research Institute. University of Toronto, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Dept of Medicine/Rheumatology, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁸U of Toronto, Toronto, ON, Canada, ⁹Dept of Medicine/Rheumatology, The Arthritis Program, Toronto Western Hospital and Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with ankylosing spondylitis (AS) are susceptible to osteoporosis (OP) and have high fracture risk. Currently, no specific strategies are established to treat OP…
Abstract Number: 1417 • 2013 ACR/ARHP Annual Meeting
Lack Of Correlation Between Golimumab Exposure and Selected Safety Events Following Intravenous Or Subcutaneous Administration In An Integrated Analysis Of Phase 3 Data Of Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Or Ankylosing Spondylitis
Jocelyn H. Leu¹, Anna Beutler¹, Alan M. Mendelsohn², Sam Liao³, Hugh M. Davis¹, Honghui Zhou¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA, ³PharMax Research, Inc., Newport Beach, CA
Background/Purpose: For anti-TNFα agents, infections and malignancies are key safety concerns. It is unknown whether safety events are driven by peak (Cmax), trough (Cmin), average…
Abstract Number: 385 • 2013 ACR/ARHP Annual Meeting
Systemic Inflammation In Patients With Inflammatory Joint Disease Does Not Influence Statin Dose Needed To Obtain Low Density Lipoprotein Cholesterol Goal In Cardiovascular Prevention
Silvia Rollefstad¹, Eirik Ikdahl², Tore K. Kvien^3,4, Terje R. Pedersen^4,5, Ingar Holme⁶ and Anne G. Semb², ¹Rhuematology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Centre of Preventive Medicine, Oslo University Hospital-Ullevaal, Oslo, Norway, ⁶Department of biostatistics, epidemiology and health economics, Oslo University Hospital-Ullevaal, Oslo, Norway
Background/Purpose: There is a lipid paradox in rheumatoid arthritis (RA): despite low lipids influenced by systemic inflammation, there is an increased risk of cardiovascular (CV)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].